Ken Griffin acquired 1.26 Million Halozyme Therapeutics shares worth $83.2 Million. That's 0.08% of their equity portfolio (315th largest holding). The investor owns 1.02% of the outstanding Halozyme Therapeutics stock. The first Halozyme Therapeutics trade was made in Q2 2013. Since then Ken Griffin bought shares 60 more times and sold shares on 51 occasions. The stake costed the investor $64.6 Million, netting the investor a gain of 29% so far.